Elimination of autoreactive B cells in humanized SCID mouse model of SLE

European Journal of Immunology

Volumn 41, Issue 11, 2011, Pages 3301-3311

  Kerekov, Nikola S ^a   Mihaylova, Nikolina M ^a   Grozdev, Ivan ^b   Todorov, Todor A ^c   Nikolova, Milena ^d   Baleva, Marta ^d   Nikolova, Maria ^e   Prechl, Jozsef ^f   Erdei, Anna ^f   Tchorbanov, Andrey I ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c Department of Pathology   (Bulgaria)

^d UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^e NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^f EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Chimeric molecules; Inhibitory B cell receptors; SCID models of SLE

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLOOD DONOR; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE; CELL SEPARATION; DISEASE MODELS, ANIMAL; DNA; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; PEPTIDES; RECEPTORS, COMPLEMENT 3B; SIGNAL TRANSDUCTION;

EID: 80054932693     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141439     Document Type: Article

References (45)

1. Lahita, R. G., The influence of sex hormones on the disease systemic lupus erythematosus. Semin. Immunopathol. 1986. 9: 305-314.
2. Shlomchik, M. J., Madaio, M. P., Ni, D., Trounstein, M. and Huszar, D., The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 1994. 180: 1295-1306.
3. Chan, O. T., Hannum, L. G., Haberman, A. M., Madaio, M. P. and Shlomchik, M. J., A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 1999. 189: 1639-1648.
4. Long, E. O., Regulation of immune responses trough inhibitory receptors. Ann. Rev. Immunol. 1999. 17: 875-904.
5. Ravetch, J. V. and Lanier, L. L., Immune inhibitory receptors. Science 2000. 290: 84-89.
6. Jozsi, M., Prechl, J., Bajtay, Z. and Erdei, A., Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J. Immunol. 2002. 168: 2782-2788.
7. Wagner, C., Ochmann, C., Schoels, M., Giese, T., Stegmaier, S., Richter, R., Hug, F. et al., The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol. Immunol. 2006. 43: 643-651.
8. Dorner, T., Therapy: hydroxychloroquine in SLE: old drug, new perspectives. Nat. Rev. Rheumatol. 2010. 6: 10-11.
9. Toubi, E., Rosner, I., Rozenbaum, M., Kessel, A. and Golan, T. D., The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000. 9: 92-95.
10. Kang, I. and Park, S. H., Infectious complications in SLE after immunosuppressive therapies. Curr. Opin. Rheumatol. 2003. 15: 528-534.
11. Klippel, J. H., Indications for, and use of, cytotoxic agents in SLE. Clin. Rheumatol. 1998. 12: 511-527.
12. Anolik, J. H., Barnard, J., Cappione, A., Pugh-Bernard, A. E., Felgar, R. E., Looney, R. J. and Sanz, I., Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004. 50: 3580-3590.
13. Anolik, J. H., Barnard, J., Owen, T., Zheng, B., Kemshetti, S., Looney, R. J. and Sanz, I., Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007. 56: 3044-3056.
14. Eisenberg, R. and Looney, R.J., The therapeutic potential of anti-CD20 "what do B-cells do?" Clin. Immunol. 2005. 117: 207-213.
15. Looney, R. J., Anolik, J. and Sanz, I., B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004. 13: 381-390.
16. Dörner, T., Kaufmann, J., Wegener, W., Teoh, N., Goldenberg, D. and Burmester, G., Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 2006. 8: R74.
17. Baker, K. P., Edwards, B. M., Main, S. H., Choi, G. H., Wager, R. E., Halpern, W. G., Lappin, P. B. et al., Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003. 48: 3253-3265.
18. Halpern, W. G., Lappin, P., Zanardi, T., Cai, W., Corcoran, M., Zhong, J. and Baker, K. P., Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. 2006. 91: 586-599.
19. Auyeung-Kim, D. J., Devalaraja, M. N., Migone, T. S., Cai, W. and Chellman, G. J., Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod. Toxicol. 2009. 28: 443-455.
20. Daëron, M. and Lesourne, R., Negative signaling in Fc receptor complexes. Adv. Immunol. 2006. 89: 39-86.
21. Nimmerjahn, F. and Ravetch, J. V., Fcgamma receptors: old friends and new family members. Immunity 2006. 24: 19-28.
22. Kaneko, Y., Nimmerjahn, F., Madaio, M. P. and Ravetch, J. V., Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 2006. 203: 789-797.
23. Tchorbanov, A. I., Voynova, E. N., Mihaylova, N. M., Todorov, T. A., Nikolova, M., Yomtova, V. M., Chiang, B. L. et al., Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 2007. 37: 3587-3596.
24. Mihaylova, N. M., Voynova, E. N., Tchorbanov, A. I., Nikolova, M., Michova, A., Todorov, T. A., Srebreva, L. et al., Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor. Int. Immunol. 2008. 20: 165-175.
25. Terstappen, L. W., Johnsen, S., Segers-Nolten, I. M. and Loken, M. R., Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990. 76: 1739-1747.
26. King-Konert, C., Stocks, S. and Weinsberg, F., First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104. Ann. Rheum. Dis. 2004. 63: 1104-1112.
27. Putterman, C., Deocharan, B. and Diamond, B., Molecular analysis of the autoantibody response in peptide-induced autoimmunity. J. Immunol. 2000. 164: 2542-2549.
28. Voynova, E., Tchorbanov, A., Prechl, J., Nikolova, M., Baleva, M., Erdei, A. and Vassilev, T., An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B lymphocytes. Immunol. Lett. 2008. 116: 168-173.
29. Steinberg, A. D., Raveche, E. S., Laskin, C. A., Smith, H. R., Santoro, T., Miller, M. L. and Plotz, P. H., NIH conference. Systemic lupus erythematosus: insights from animal models. Ann. Intern. Med. 1984. 100: 714-727.
30. Mountz, J. D., Gause, W. C. and Jonsson, R., Murine models for systemic lupus erythematosus and Sjogren's syndrome. Curr. Opin. Rheumatol. 1991. 3: 738-756.
31. Theofilopoulos, A. N. and Dixon, F. J., Murine models of systemic lupus erythematosus. Adv. Immunol. 1985. 37: 269-390.
32. Cohen, P. L. and Eisenberg, R. A., Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Ann. Rev. Immunol. 1991. 9: 243-269.
33. Izui, S., Ibnou-Zekri, N., Fossati-Jimack, L. and Iwamoto, M., Lessons from BXSB and related mouse models. Int. Rev. Immunol. 2000. 19: 447-472.
34. Merino, R., Fossati, L. and Izui, S., The lupus-prone BXSB strain: the Yaa gene model of systemic lupus erythematosus. Springer Semin. Immunopathol. 1992. 14: 141-157.
35. Furukawa, F. and Yoshimasu, T., Animal models of spontaneous and drug-induced cutaneous lupus erythematosus. Autoimmun. Rev. 2005. 4: 345-350.
36. Furukawa, F., Tanaka, H., Sekita, K., Nakamura, T., Horiguchi, Y. and Hamashima, Y., Dermatopathological studies on skin lesions of MRL mice. Arch. Dermatol. Res. 1984. 276: 186-194.
37. Hang, L., Theofilopoulos, A. N. and Dixon, F. J., A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J. Exp. Med. 1982. 155: 1690-1701.
38. Koopman, W. J. and Gay, S., The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand. J. Rheumatol. Suppl. 1988. 75: 284-289.
39. Mauermann, N., Sthoeger, Z., Zinger, H. and Mozes, E., Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin. Exp. Immunol. 2004. 137: 513-520.
40. Sthoeger, Z., Zinger, H., Dekel, B., Arditi, F., Reisner, Y. and Mozes, E., Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras. J. Clin. Immunol. 2003. 23: 91-99.
41. Vladutiu, A. O., The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases. Clin. Exp. Immunol. 1993. 93: 1-8.
42. Mihaylova, N., Voynova, E., Tchorbanov, A., Dolashka-Angelova, P., Bayry, J., Devreese, B., Kaveri, S. and Vassilev, T., Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. Mol. Immunol. 2009. 47: 123-130.
43. Mohan, C., Adams, S., Stanik, V., Datta, S. K., Nucleoside: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 1993; 177: 1367-1381.
44. Bauminger, S. and Wilchek, M., The use of carbodiimides in the preparation of immunizing conjugates. Methods Enzymol. 1980. 70: 151-159.
45. Sundström, C. and Nilsson, K., Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 1976. 17: 565-577.